UFP Technologies to Present and Host 1X1 Investor Meetings at the Raymond James 47th Annual Institutional Investors Conference

UFP Technologies, Inc. (Nasdaq: UFPT), a prominent player in the contract development and manufacturing sector, focuses on single-use and single-patient medical devices. The company has announced its participation in the upcoming Raymond James 47th Annual Institutional Investors Conference, scheduled for March 1-4, 2026, in Orlando, Florida. Key executives, Chairman and CEO R. Jeffrey Bailly along with CFO Ron Lataille, will represent the company, with UFP’s presentation set to start at 2:50 PM on March 3rd. A live webcast of this presentation will be available for investors and interested parties.

UFP Technologies serves as an essential link in the medical device supply chain, partnering with some of the world’s leading medical device manufacturers. Its expertise lies in the creation of single-use and single-patient devices and components that play a critical role in a variety of medical applications. These include minimally invasive surgery, infection prevention, wound care, and both orthopedic soft goods and implants. The company’s robust portfolio of products underscores its commitment to advancing healthcare through innovation and high-quality manufacturing, catering to an increasing demand for specialized medical solutions.

Investors can contact CFO Ron Lataille directly at 978-234-0926 or via email for further inquiries, or reach out to Jeff Elliott at Three Part Advisors for additional information regarding the conference and UFP's strategic direction. This engagement at the Raymond James conference reflects UFP Technologies’ ongoing efforts to connect with institutional investors and highlight its pivotal role in the dynamic medical device industry.

As UFP Technologies, Inc. (Nasdaq: UFPT) prepares to present at the Raymond James 47th Annual Institutional Investors Conference, investor interest is likely to center around its pivotal role in the medical device industry. UFP specializes in single-use medical devices, and its positioning as an outsourcing partner for leading manufacturers underscores its relevance in a growing market.

The upcoming presentation by UFP’s CEO and CFO offers a platform for the company to outline its strategic initiatives, financial health, and market outlook. Investors should take note of the expanding need for single-use and patient-specific devices, bolstered by trends toward minimally invasive procedures and an emphasis on infection control in healthcare settings. UFP's capabilities in custom manufacturing and innovative design may provide a competitive advantage, particularly as the medical device landscape evolves.

From a financial perspective, analysts should monitor UFP's sales growth trajectory, particularly in high-demand segments such as orthopedic and wound care applications. Given the broader trends in healthcare spending and an aging population, demand for UFP’s products is expected to remain robust. Furthermore, as the company continues to strengthen its partnerships with major device manufacturers, it could enhance its revenue streams and operational efficiencies.

For potential investors, it will be critical to assess UFP's recent financial statements and forecasts during the conference. Look for insights on top-line growth, profit margins, and any emerging challenges related to supply chain dynamics or regulatory hurdles. Monitoring investor sentiment following the presentation will also be key, as it could affect stock liquidity and valuation.

In summary, UFP Technologies presents an interesting investment opportunity, particularly for those focused on the healthcare manufacturing sector. Given its established presence, innovative capabilities, and market relevance, UFP may merit serious consideration in a diversified portfolio.